Pfizer and biontech confirm high efficacy and no serious safety concerns through up to six months following second dose in updated topline analysis of landmark covid-19 vaccine study

New york and mainz, germany, april 1, 2021 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced updated topline results from analysis of 927 confirmed symptomatic cases of covid-19 observed in their pivotal phase 3 study through march 13, 2021, showing that the pfizer-biontech covid-19 vaccine, bnt162b2, was 91.3% effective against covid-19, measured seven days through up to six months after the second dose. the vaccine was 100% effective against severe disease as defined by the u.s. centers for disease control and prevention (cdc), and 95.3% effective against severe covid-19 as defined by the u.s. food and drug administration (fda). safety data from the phase 3 study has also been collected from more than 12,000 vaccinated participants who had a follow-up time of at least six months after the second dose, demonstrating a favorable safety and tolerability profile.
BNTX Ratings Summary
BNTX Quant Ranking